Versant Ventures and Novartis led a $150m Series A round in Borealis Biosciences.

Versant Ventures, an American Venture capital firm, and Novartis, a Swiss multinational pharmaceutical corporation, led a $150m Series A round in Borealis Biosciences, a biotechnology company. “We’ve recognized over the last six years that some of the most validated targets for kidney disease have been out of reach with traditional modalities. Borealis has the potential to address these targets and reach patients most in need. We are excited to launch this startup in close collaboration with Novartis, as this represents another example of Versant’s creative company-building together with an industry leader,” Jerel Davis, Versant Managing Director.